Oral Hepatoselective Glucokinase Activator Promising in T2DM

FRIDAY, Jan. 18, 2019 -- Use of the oral hepatoselective glucokinase activator (GKA) TTP399 for type 2 diabetes does not cause hypoglycemia and has no detrimental effect on plasma lipids or liver enzymes, according to a study published online Jan....